English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Juvenile idiopathic arthritis (JIA) is a severe disabling disease affecting paediatric population. 507 children with JIA are monitored in Chelyabinsk region. Oligo-articular and poly-articular types of JIA are often associated with affection of eyes (uveitis). In patients resistant to traditional basic treatment (methotrexate and cyclosporine) F-alpha inhibitors are recommended. Adalimumab, approved for treatment of children older than 4 years in the Russian Federation, is a treatment of choice in patients with JIA associated with uveitis.

Administration of adalimumab in paediatric patients with juvenile idiopathic arthritis in South Ural region